Trial Profile
The effect of denosmab on osteoporosis related to Parkinson's disease and glucocorticoid-induced osteoporosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Sep 2020
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 05 Sep 2020 Status changed from recruiting to completed.
- 01 Dec 2016 New trial record